Vetter Once Again Named Best Managed Company
RAVENSBURG, Germany--(BUSINESS WIRE)--May 27, 2025--
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has been named Best Managed Company in its anniversary year for the sixth time in a row. For 75 years, the family-owned company has stood for quality, responsibility, and a strong commitment to improving the quality of life of patients worldwide. The award demonstrates how Vetter pursues its strategic goals in a focused and action-driven manner. The jury recognizes the company's long-term thinking as a key success factor. The Best Managed Companies Award is organized by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung, and the Bundesverband der Deutschen Industrie e.V. (Federation of German Industries). The trophy and certificate were presented to the CDMO at an awards ceremony on May 22 at the Gesellschaftshaus Palmengarten in Frankfurt, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527162693/en/
Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family (second from right) along with Vetter Managing Director Titus Ottinger (second from left), Holger Loesch, Deputy Director General of the Federation of German Industries (first from left) and moderator Susanne Schoene, at the presentation of the Best Managed Companies Award.
Markus Seiz, Best Managed Companies Program Lead and Director at Deloitte Private says: 'Vetter is an example of how critical it is for actions to align with core values in order to achieve economic success as a globally active family business. In our opinion, the trusted pharmaceutical service provider is one of the pioneers of sustainable and innovative corporate management in the way it combines its strategic vision and responsible business practices.'
To earn the Best Managed Companies Award, a company must convince the high-caliber jury across four key business areas known as 'value drivers,' including: strategy; productivity and innovation; culture and commitment; and governance and finance. After a personal coaching session, the participating companies answer an extensive and detailed questionnaire. In 2025, for the first time, the jury also evaluated criteria that are geared towards the specific values and unique profiles of family businesses. Vetter impressed in all four areas due to its consistency in driving forward and developing its projects and processes in line with its corporate values.
Vetter Managing Director Titus Ottinger emphasizes: 'Participating in the Best Managed Companies Award enables us to receive valuable feedback through a stringent external selection process. This feedback is very important for us, as it comes from experienced professionals in a wide range of fields, whose perspectives allow us to further grow. This year, we were able to show even more explicitly how deeply we have anchored the values of our family business in our day-to-day operations. This new facet of the program makes the award even more valuable to us.'
With 11% sales growth reaching 1.1 billion euros in 2024, Vetter demonstrates how its consistent focus on all four value drivers results in meaningful business outcomes. The results for 2024 are also positive in other areas. For example, the CDMO continued its growth in employment, now with 7,000 global employees. With investments of 269 million euros in the expansion and modernization of its sites in Germany, Austria, and the U.S., Vetter continues to invest in its dynamic and organic growth in the production of complex injectable drugs. In a politically and economically challenging environment, the CDMO is proving to be a secure employer and reliable partner for pharma and biotech companies worldwide.
The strategic focus of the company's development in 2024 was once again on the reliability and high-quality of the services offered, sustainable growth, and advancing digital transformation in all facets of the company. Numerous projects for the digitization of production processes and in the areas of AI, human-machine interaction, cloud and cyber security are currently underway or have already been completed. With a comprehensive innovation management process characterized by interactive formats, Vetter's employees prioritize identifying trends and technologies early on. For many years, the CDMO has placed a strategic focus on sustainability in the areas of ecology, economy, and social issues. The family-owned company published its fourth comprehensive sustainability report earlier this year.
The Vetter press kit and additional information are available in the digital press area.
About Vetter
Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world, small and large renowned pharma and biotech companies rely on the decades of experience, high quality, modern technologies, reliability, and commitment of its more than 7,000 employees. In close partnership with its customers, the Vetter team supplies patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative solutions, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. The company is an industry pioneer in sustainability and a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received gold status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition as Best Managed Company emphasize Vetter's commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250527162693/en/
CONTACT: Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Eywiesenstrasse 5
88212 Ravensburg,
Germany
Phone: +49 (0)751-3700-3729
E-mail:[email protected]
KEYWORD: GERMANY EUROPE UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY MANUFACTURING HEALTH PHARMACEUTICAL PACKAGING
SOURCE: Vetter Pharma International GmbH
Copyright Business Wire 2025.
PUB: 05/27/2025 08:24 AM/DISC: 05/27/2025 08:22 AM
http://www.businesswire.com/news/home/20250527162693/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Frost & Sullivan Released Report: "2025 China Pharmaceutical CDMO Industry Insight Blue Book"
Shanghai, China--(Newsfile Corp. - June 19, 2025) - Frost & Sullivan released the "2025 China Pharmaceutical CDMO Industry Insight Blue Book", a comprehensive analysis of the evolution and strategic trajectory of China's pharmaceutical Contract Development and Manufacturing Organization (CDMO) sector. Rooted in an in-depth examination of market dynamics, technological innovation, and global competitiveness, the report elucidates how China's CDMO industry is reshaping the global pharmaceutical value chain through specialized services, operational agility, and cutting-edge capabilities. (To read the Blue Book, go here: "2025 China Pharmaceutical CDMO Industry Insight Blue Book " highlights the following: The Core Position of the CDMO Sector: How CDMOs support pharmaceutical companies across the entire drug development and manufacturing value chain. Four Development Stages of China's CDMO Industry: From Policy Liberalization to Global Competition, tracing the evolution and growth of China's CDMO sector. Dual-Engine Phase of Scale Expansion and Domain Segmentation: The expansion and specialization trends within China's CDMO industry. Sub-sectors of CDMO: Detailed insights into Small Molecule, Peptide, Antibody, ADC, and CGT CDMO segments. Multi-Point Growth Pattern: The diverse growth points and strategic developments of China's CDMO industry. Introduction to Selected Chinese CDMOs: Showcasing leading CDMOs in China and their contributions to the industry, including BiBo Pharma, Healthnice, Porton Pharma, ChemExpress, OBiO Technology, Pharmaron, PharmaBlock, Yaohai Bio-Pharma, uBriGene, Intellective Bio, Chinese Peptide, and TOT Biopharm. The CDMO Sector Holds a Core Position in the Pharmaceutical Industry As a major part of the outsourcing pharmaceutical service industry, CDMOs support pharmaceutical companies across the entire chain, from drug discovery to market launch, and from process development to large-scale manufacturing. They rely on large-scale production capacity and high value-added R&D and manufacturing processes. As a result, CDMOs have become key partners and hold a core position in China's pharmaceutical industry. Demand Drives Expansion and Subdivision of CDMOs The continued evolution of global demand for biopharmaceutical R&D and manufacturing is pushing China's CDMO industry into a dual-engine phase of scale expansion and domain segmentation. On one hand, the increasing technical complexity of emerging areas such as CGT, ADCs, and nucleic acid drugs is driving strong demand for specialized CDMO services. On the other hand, traditional segments like small molecule drugs continue to expand production capacity due to process optimization and steady market demand. At the same time, differentiated demands from pharmaceutical companies are accelerating the diversification of service models. Biopharma companies tend to divest non-core manufacturing functions to focus on innovative pipelines, thereby driving CDMOs toward high-end process development. Biotech firms, constrained by resources, increasingly rely on one-stop services that provide full-cycle support from target validation to IND filing, prompting the rise of full-chain CDMO platforms. In response, Chinese CDMOs are using technological deployment and service model innovation to build entry barriers in niche areas while using large-scale production capacity to capture global orders, thus establishing a dual-path development model of "high-end breakthroughs + foundational consolidation."。 Four Development Stages : Policy, Technology, and Capital-Driven the Closed-Loop Growth of China's CDMO Industry China's pharmaceutical CDMO industry has gone through four key stages: policy liberalization, technology transfer, capital-driven growth, and global competition. The sector has moved from the early phase of reliant on foreign technology and policy incentives to a more advanced stage defined by deep technical expertise, global production layout, and integrated ecosystems. On the policy side, the implementation of the MAH system, stricter GMP standards, and medical insurance reform have pushed pharmaceutical companies to separate their manufacturing functions, creating strong demand for CDMO services. On the technology side, advancements in continuous flow chemistry, enzymatic catalysis, and AI-based drug design have increased the added value of services. On the capital side, funding has fueled the rise of emerging fields. The industry now follows a closed-loop development model: policy-driven demand-technology-driven service upgrades-capital-driven expansion-global ecosystem integration. This reflects a shift in China's CDMO sector from rapid scale expansion to high-quality development. A Multi-Front Development Trend of China's CDMO Industry Chinese CDMO enterprises are strategically advancing vertically integrated service capabilities across the pharmaceutical value chain through organic growth and strategic mergers, aligning with China's push for high-quality industrial development. As sector competition intensifies, differentiation through niche specialization has become critical. To address global capacity imbalances and optimize biologics production economics, CDMOs are prioritizing operational efficiency upgrades and smart manufacturing adoption. Leading players are simultaneously executing multi-pronged globalization strategies: establishing GMP-compliant facilities in key overseas markets to secure long-term international competitiveness, while deepening technological moats through specialized R&D investments in advanced modalities. This dual approach enables breakthroughs in traditional competitive frameworks through differentiated capabilities. Global capacity networks are being rapidly expanded in overseas production hubs and acquisitions of internationally certified manufacturers, forming interconnected supply chains aligned with global pharmaceutical collaboration systems. Simultaneously, innovative CRDMO models are integrating value chain resources to create end-to-end service ecosystems spanning drug discovery to commercial manufacturing. Case studies including BiBo Pharma, Porton Pharma, Healthnice, ChemExpress, OBiO Technology, Pharmaron, PharmaBlock, Yaohai Bio-Pharma, uBriGene, Intellective Bio and Chinese Peptide exemplify the diversified growth trajectories shaping China's CDMO landscape. These enterprises demonstrate how strategic focus on technological innovation, operational excellence, and global integration is redefining the sector's competitive dynamics. About Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 60 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Media ContactContact: Qian LiCompany Name: Frost & SullivanWebsite: To view the source version of this press release, please visit
Associated Press
5 days ago
- Associated Press
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific's Accelerator™ Drug Development 360° CDMO and CRO Solutions
WALTHAM, Mass.--(BUSINESS WIRE)--Jun 16, 2025-- Thermo Fisher Scientific Inc., the world leader in serving science, today announced the findings of new research by the Tufts Center for the Study of Drug Development (CSDD) demonstrating the benefits of the company's Accelerator™ Drug Development 360° CDMO and CRO solutions in helping biotech and biopharma companies speed life-changing medicines to patients. 1 The findings show Thermo Fisher's integrated services can potentially reduce drug development timelines by up to nearly three years, representing significant time savings on the average 10 to 15 years it takes to commercialize a new drug. Streamlining drug development is crucial for biotech and biopharma companies facing high development costs, regulatory complexity and the urgent need to bring safe, new medicines to market more quickly. Drug developers traditionally have relied on multiple supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions; however, this decentralized approach leads to inefficiency, miscommunication and delay. Each month of delay in a Phase III clinical trial can result in up to $8 million in lost revenue resulting from shortened market exclusivity and deferred market entry. 2 The Tufts CSDD study demonstrates that working with an integrated partner to provide contract development and manufacturing organization (CDMO) and clinical research organization (CRO) solutions can help speed and streamline the complex journey of drug development. Accelerator™ Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services at every stage of development. To date, more than 120 biotech and biopharma companies have worked with Thermo Fisher across its integrated CDMO and CRO solutions on more than 350 protocols across therapeutic areas, small molecule, large molecule and advanced therapies. 'This new study highlights the opportunity to deliver safe new medicines to patients significantly faster,' said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific. 'Through Accelerator Drug Development, we are well positioned to bring customizable, end-to-end solutions and world-leading expertise to our customers, and we're proud of the capabilities we've built to meet customer and patient needs.' The Tufts CSDD study reported that using integrated services from Phase I through Phase III can reduce drug development times by up to 34 months. Researchers also found that integrated CRO/CDMO services can generate up to $63 million in net financial benefits for drug sponsors, a return on investment of up to 113 times the initial investment. In considering multiple scenarios across phases of drug development and different levels of investment in integrated services, researchers found demonstrable time savings and ROI across the board, reflecting the benefits of integration, such as cross-functional program coordination, collaboration, oversight, planning and communication. 'This study,' the authors wrote, 'demonstrates that integration of services across development and manufacturing functions can yield substantial benefits to drug sponsors in the form of shorter clinical development durations. The findings from this study provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies.' The study's lead author, Joseph DiMasi, Ph.D., director of economic analysis and research associate professor, Tufts University, said, 'The cost of developing new drugs is exacerbated by operational inefficiencies from the siloing of clinical research, drug manufacturing and supply chain functions. Our findings underscore the strategic importance of integrated services as a driver of value. Drug sponsors considering this approach should consider the degree of integration that would drive the most value for their programs. Our study reveals that while fully integrated service provision yields the greatest financial benefit, even partial integration offers significant value, especially for the later phases of clinical development.' To learn more, please visit Thermo Fisher Scientific's website. Additionally, Thermo Fisher will showcase its latest innovative and flexible solutions in support of biotechnology and biopharmaceutical companies at every stage of their drug development journey during the 2025 BIO International Convention, June 16-19 (booth #2953). Leaders from across the organization will also participate in a series of panel discussions that will highlight industry trends, strategies for sustainability and the value of collaboration to bring medicines to market faster. 1 The research was supported in part by a grant from Thermo Fisher Scientific to the Tufts Center for the Study of Drug Development. Tufts CSDD maintains a strong reputation for scholarly and objective insights drawn from hard evidence. The results of all research conducted by Tufts CSDD remain independent and are published in peer-reviewed and trade journals. The study, which researchers believe to be the first of its kind, modeled the net financial benefit of integrated CDMO-CRO services Thermo Fisher provided to customers in recent years using a risk-adjusted, discounted cash flow analysis (also known as an expected net present value analysis). While the study focused on oncology drug development scenarios, the findings may have applications more broadly across other therapeutic areas. 2 Rubio-Herrero, Javier, Anh Ninh, and Michael Lefew. 2023. 'Improving the Performance of Supply Chains in Clinical Trials with Delays: An Optimization Approach to Determining the Number of Recruitment Sites.' Annals of Operations Research. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on CONTACT: Media Contact Information: Ned Glascock E-mail:[email protected] Website: Morton E-mail:[email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Thermo Fisher Copyright Business Wire 2025. PUB: 06/16/2025 08:15 AM/DISC: 06/16/2025 08:14 AM
Associated Press
6 days ago
- Associated Press
Samsung Biologics launches drug screening services, Samsung Organoids
INCHEON, South Korea, June 15, 2025 /PRNewswire/ -- Samsung Biologics (KRX: a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development. Organoids are three-dimensional cell culture systems engineered to closely mimic human organs, offering clinically relevant insights to better understand specific drug responses and improve lead selection. Organoids are emerging as a new research model due to their high similarity to live tissues and potential applications in biomarker discovery and drug efficacy prediction. Samsung Organoids support precision screening to predict patient responses, streamline preclinical development, and accelerate timelines toward investigational new drug (IND) filings through data-driven analysis of candidate molecules. With the launch, Samsung Biologics expands its business to include preclinical research, with service offerings spanning target discovery, lead selection, preclinical development, and clinical trial planning. Leveraging its expertise in development and manufacturing, the company will provide data-driven, multi-modal insights into the characteristics and mechanisms of candidate molecules. By helping clients address challenges that may arise during the drug discovery phase, Samsung Biologics aims to enhance clinical success rates. 'The latest service launch reflects our unwavering commitment to driving innovation by improving drug success rates and creating new possibilities in personalized medicine,' said John Rim, CEO and President of Samsung Biologics. 'The addition of research services is a significant move for us to create added value for clients by supporting the drug life cycle from start to finish with thorough therapeutic analysis.' About Samsung Biologics Samsung Biologics (KRX: is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health. For more information, please visit Samsung Biologics Media Contact Claire Kim [email protected] View original content to download multimedia: SOURCE Samsung Biologics
